CanBas Co Ltd
4575
Company Profile
Business description
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Contact
2-2-1 Otemachi
Numazu
Shizuoka410-0891
JPNT: +81 559543666
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
11
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,866.08 | 44.08 | 0.56% |
| DAX 40 | 24,446.96 | 76.03 | 0.31% |
| Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
| FTSE 100 | 8,993.00 | 20.36 | 0.23% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,885.65 | 155.16 | 0.75% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,297.36 | 33.66 | 0.54% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |